Telomeres and marrow failure.
Telomeres, repeat sequences at the ends of chromosomes, are protective chromosomal structures highly conserved from primitive organisms to humans. Telomeres inevitably shorten with every cell cycle, and telomere attrition has been hypothesized to be fundamental to normal senescence of cells, tissues, and organisms. Molecular mechanisms have evolved to maintain their length and protective function; telomerase (TERT) is a reverse transcriptase enzyme that uses an RNA molecule (TERC) as the template to elongate the 3' ends of telomeres. Shelterin is a collection of DNA-binding proteins that cover and protect telomeres. The recent discovery of inherited mutations in genes that function to repair telomeres as etiologic in a range of human diseases, which have clinical manifestations in diverse tissues, including the hematopoietic tissue, suggests that defects in telomere repair and protection can cause organ failure. Dyskeratosis congenita is the prototype of telomere diseases; it is characterized by bone marrow failure, mucocutaneous abnormalities, pulmonary fibrosis, liver cirrhosis, and increased susceptibility to cancer, including acute myeloid leukemia. Aplastic anemia, acute myeloid leukemia, and idiopathic pulmonary fibrosis also are associated with inherited mutations in telomere repair or protection genes. Additionally, telomere defects associate with predisposition to hematologic malignancy and epithelial tumors. Telomere erosion is abnormally rapid in patients with mutations in telomerase genes but also after hematopoietic stem cell transplant, and telomeres are naturally shorter in older individuals-all conditions associated with higher rates of malignant diseases. In human tissue culture, short telomeres produce end-to-end chromosome fusion, nonreciprocal translocations, and aneuploidy.
Calado
Rodrigo T
RT
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892-1202, USA. calador@nhlbi.nih.gov
D000208:Acute Disease; D000741:Anemia, Aplastic / Q000175:diagnosis / Q000235:genetics / Q000473:pathology; D001855:Bone Marrow Diseases / Q000175:diagnosis / Q000235:genetics / Q000473:pathology*; D002471:Cell Transformation, Neoplastic; D016922:Cellular Senescence; D043171:Chromosomal Instability; D002869:Chromosome Aberrations; D002877:Chromosomes, Human / Q000648:ultrastructure*; D019871:Dyskeratosis Congenita / Q000175:diagnosis / Q000235:genetics / Q000473:pathology; D005260:Female; D006801:Humans; D054990:Idiopathic Pulmonary Fibrosis / Q000175:diagnosis / Q000235:genetics / Q000473:pathology; D007951:Leukemia, Myeloid / Q000175:diagnosis / Q000235:genetics / Q000473:pathology; D008297:Male; D009369:Neoplasms / Q000235:genetics / Q000473:pathology; D009386:Neoplastic Syndromes, Hereditary / Q000175:diagnosis / Q000235:genetics / Q000473:pathology; D012313:RNA / Q000235:genetics / Q000502:physiology; D000089804:Shelterin Complex; D019098:Telomerase / Q000235:genetics / Q000502:physiology; D016615:Telomere / Q000187:drug effects / Q000648:ultrastructure*; D034501:Telomere-Binding Proteins / Q000502:physiology
D000089804:Shelterin Complex; D034501:Telomere-Binding Proteins; C422952:telomerase RNA; D012313:RNA; C509186:TERT protein, human; D019098:Telomerase